On track to become a leading European biotech
22 years of ground-breaking research and development
10 years partnership formed with Gilead in 2019
An increasing global reach
Over 1300 employees globally
9 International locations
R&D is at the heart of our business
60% of employees work in R&D
74% of operating expenses are in R&D
Galapagos’ mission is to develop first-in-class medicines based on the discovery of novel targets. Galapagos researchers have gone from target to proof of concept in three lead programs addressing broad disease categories affecting millions worldwide.
Using human primary cells and patient cells, the company discovers which proteins ("targets") play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease, fibrosis and kidney disease. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the disease itself rather than just treating the symptoms.
Galapagos' aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet need.
Galapagos conducts Phase 1 trials in healthy volunteers in centers which are specifically equipped for this purpose, with the aim to test the safety, tolerability and …
We’re not only looking for scientists. We’re looking for pioneers in a wide range of domains: The best-in-class doctors, …
Our commitment to Corporate Social Responsibility (CSR) is intrinsically linked to our core mission: to discover and develop …